Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;100:2018-2024

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lundell, A.
Right arrow Articles by Harker, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lundell, A.
Right arrow Articles by Harker, L. A.
Related Collections
Right arrow Animal models of human disease
Right arrow Anticoagulant mechanisms
Right arrow Platelets

(Circulation. 1999;100:2018-2024.)
© 1999 American Heart Association, Inc.


Basic Science Reports

Reduction in Vascular Lesion Formation by Hirudin Secreted From Retrovirus-Transduced Confluent Endothelial Cells on Vascular Grafts in Baboons

Anders Lundell, MD, PhD; Andrew B. Kelly, DVM; Johanna Anderson, MS; Monique Marijianowski, PhD; Jeffrey J. Rade, MD; Stephen R. Hanson, PhD; Laurence A. Harker, MD

From the Division of Hematology and Oncology and Yerkes Regional Primate Research Center, Emory University School of Medicine, Atlanta, Ga, and the Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Md (J.J.R.).

Correspondence to Laurence A. Harker, MD, Blomeyer Professor and Director, Division of Hematology and Oncology, Emory University School of Medicine, 1639 Pierce Dr, Room 1003, Atlanta, GA 30322.

Background—The hypothesis that thrombin mediates the formation of neointimal vascular lesions at sites of mechanical vascular injury has been tested in baboons by measurement of the effects of hirudin delivered by retrovirus-transduced hirudin-secreting vascular endothelial cells (ECs) lining surgically implanted arterial vascular grafts (AVGs).

Methods and Results—The antithrombotic efficacy of baboon ECs transduced with cDNA encoding hirudin was assessed in vitro and in vivo on thrombogenic segments in chronically exteriorized femoral arteriovenous (AV) shunts. Bilateral brachial AVGs lined with hirudin-transduced versus nonhirudin control ECs at confluent density were surgically implanted, and vascular lesion formations at distal graft-vessel anastomoses were compared after 30 days. Hirudin-transduced ECs secreted 20±6 ng · 106 cells-1 · 24 h-1 (range, 14 to 24 ng · 106 cells-1 · 24 h-1) hirudin in supernatants of static cultures. Hirudin-secreting ECs on segments of collagen-coated graft interposed in chronic AV shunts decreased the accumulation of 111In-labeled platelets to 0.52±0.34x109 platelets, compared with 0.82±0.49x109 platelets in controls (P=0.03) and reduced platelet deposition in propagated thrombotic tails extending downstream from segments of vascular graft from 1.38±0.41x109 platelets in controls to 0.59±0.22x109 platelets (P=0.04). ECs recovered from 30-day AVG implants generated 17±9 ng · 106 cells-1 · 24 h-1 (range, 9 to 25 ng · 106 cells-1 · 24 h-1) hirudin. Hirudin-secreting ECs reduced neointimal lesion formation at distal graft-vessel anastomoses, ie, 1.02 mm2 (range, 0.88 to 1.95 mm2) versus 1.82 mm2 (range, 0.88 to 2.56 mm2) in contralateral AVGs bearing nonhirudin control ECs (P<0.01).

Conclusions—Viral vector–directed secretion of hirudin from ECs lining implanted AVGs significantly reduces the formation of thrombus and neointimal vascular lesions.


Key Words: lesion • anticoagulants • viruses • grafting




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau
Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease
Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1761 - 1774.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau
Gene- and cell-based therapies for cardiovascular diseases: current status and future directions
Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35.
[Abstract] [Full Text]


Home page
FASEB J.Home page
A. T. KOVALA, K. A. HARVEY, P. McGLYNN, G. BOGUSLAWSKI, J. G. N. GARCIA, and D. ENGLISH
High-efficiency transient transfection of endothelial cells for functional analysis
FASEB J, December 1, 2000; 14(15): 2486 - 2494.
[Abstract] [Full Text]